{
  "guideline" : {
    "objCls" : "Guideline",
    "@id" : "https://api.pharmgkb.org/data/guideline/PA166104997",
    "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
    "id" : "PA166104997",
    "name" : "CPIC Guideline for abacavir and HLA-B",
    "descriptiveVideoId" : "XsQiUeeYWMM",
    "history" : [ {
      "id" : 1183699748,
      "date" : "2012-02-29T00:00:00-08:00",
      "type" : "update",
      "version" : 0
    }, {
      "id" : 1183847536,
      "date" : "2014-02-28T00:00:00-08:00",
      "description" : "CPIC update to guidelines published",
      "type" : "update",
      "version" : 0
    }, {
      "id" : 1184512476,
      "date" : "2014-08-05T00:00:00-07:00",
      "description" : "updated pubication date for update to May 2014",
      "type" : "update",
      "version" : 1
    }, {
      "id" : 1184782525,
      "date" : "2014-09-30T00:00:00-07:00",
      "description" : "Supplement was missing figures; complete supplement with figures added",
      "type" : "correction",
      "version" : 1
    } ],
    "relatedChemicals" : [ {
      "objCls" : "Chemical",
      "@id" : "https://api.pharmgkb.org/data/chemical/PA448004",
      "@context" : "https://www.pharmgkb.org/jsonld/chemical.jsonld",
      "id" : "PA448004",
      "name" : "abacavir",
      "version" : 7
    } ],
    "relatedGenes" : [ {
      "objCls" : "Gene",
      "@id" : "https://api.pharmgkb.org/data/gene/PA35056",
      "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
      "id" : "PA35056",
      "symbol" : "HLA-B",
      "name" : "major histocompatibility complex, class I, B",
      "version" : 39
    } ],
    "source" : "CPIC",
    "summaryMarkdown" : {
      "id" : 1447982036,
      "externalLinks" : [ ],
      "html" : "<p>In individuals with the HLA-B*57:01 variant allele (&quot;HLA-B*57:01-positive&quot;), abacavir is not recommended and should be considered only under exceptional circumstances. See full guideline for disclaimers, further details and supporting evidence.</p>\n",
      "internalLinks" : [ ],
      "markdown" : "In individuals with the HLA-B*57:01 variant allele (\"HLA-B*57:01-positive\"), abacavir is not recommended and should be considered only under exceptional circumstances. See full guideline for disclaimers, further details and supporting evidence.",
      "pmids" : [ ],
      "relatedObjects" : [ ],
      "version" : 0
    },
    "summaryVideoId" : "M60aQ9PtwuE",
    "terms" : [ {"@id":"https://api.pharmgkb.org/data/ontologyTerm/cpicStatus/cpicStatus:1183847844","@context":"https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":1183847844,"resource":"CPIC Status","term":"A","termId":"cpicStatus:1183847844"} ],
    "textMarkdown" : {
      "id" : 1447982035,
      "externalLinks" : [ "http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf", "http://www.nature.com/clpt/journal/v95/n5/full/clpt201438a.html", "http://www.theaidsreader.com/display/article/1145619/2064707", "https://github.com/PharmGKB/cpic-guidelines/raw/master/abacavir/2012/22378157-supplement.pdf", "https://github.com/PharmGKB/cpic-guidelines/raw/master/abacavir/2012/22378157.pdf", "https://github.com/PharmGKB/cpic-guidelines/raw/master/abacavir/2014/24561393-supplement.pdf", "https://github.com/PharmGKB/cpic-guidelines/raw/master/abacavir/2014/24561393.pdf" ],
      "html" : "<h3 id=\"may-2014\">May 2014</h3>\n<p><em>Accepted article preview online 21 February 2014; Advance online publication 12 March 2014</em></p>\n<p>The <a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=http%3A%2F%2Fwww.nature.com%2Fclpt%2Fjournal%2Fv95%2Fn5%2Ffull%2Fclpt201438a.html\" target=\"_blank\">2014 update of CPIC guidelines</a> regarding abacavir has been published in <em>Clinical Pharmacology and Therapeutics</em>. Literature published between April 2011-November 2013 was reviewed and there is <strong>no new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current</strong>.</p>\n<ul>\n<li>These guidelines are applicable to:\n<ul>\n<li>HIV Patients</li>\n</ul>\n</li>\n<li>Download and read:\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fabacavir%2F2014%2F24561393.pdf\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium Guidelines for <em>HLA-B</em> Genotype and Abacavir Dosing: 2014 Update </a>.</li>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fabacavir%2F2014%2F24561393-supplement.pdf\" target=\"_blank\">2014 supplement</a>.</li>\n</ul>\n</li>\n</ul>\n<h3 id=\"april-2012\">April 2012</h3>\n<p><em>Advance online publication February 2012</em></p>\n<ul>\n<li>Download and read:\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fabacavir%2F2012%2F22378157.pdf\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium Guidelines for <em>HLA-B</em> Genotype and Abacavir Dosing</a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fabacavir%2F2012%2F22378157-supplement.pdf\" target=\"_blank\">2012 supplement</a>.</li>\n</ul>\n</li>\n</ul>\n<p>Excerpt from the abacavir dosing guidelines:</p>\n<blockquote class=\"blockquote\">\n<p>We agree with others* that <em>HLA-B*57:01</em> screening should be performed in all abacavir-naive individuals before initiation of abacavir-containing therapy (see Table 1 below); this is consistent with the recommendations of the FDA, the US Department of Health and Human Services, and the European Medicines Agency. In abacavir-naive individuals who are <em>HLA-B*57:01</em>-positive, abacavir is not recommended and should be considered only under exceptional circumstances when the potential benefit, based on resistance patterns and treatment history, outweighs the risk.</p>\n</blockquote>\n<p>*[Articles:<a href=\"/pmid/18826546\">18826546</a>, <a href=\"/pmid/19640227\">19640227</a>, <a href=\"/pmid/21174626\">21174626</a>, <a href=\"/pmid/21412232\">21412232</a>] <a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=http%3A%2F%2Fwww.aidsinfo.nih.gov%2FContentFiles%2FAdultandAdolescentGL.pdf\" target=\"_blank\">Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (PDF) </a></p>\n<h3 id=\"table-1-recommended-therapeutic-use-of-abacavir-based-on-hla-b-genotype\">Table 1: Recommended therapeutic use of abacavir based on <em>HLA-B</em> genotype</h3>\n<p><em>Adapted from Tables 1 and 2 of the 2012 guideline manuscript.</em></p>\n<table class=\"table\">\n<thead>\n<tr><th>Likely phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications for phenotypic measures</th><th>Recommendations for abacavir therapy</th><th>Classification of recommendation for abacavir therapy <sup>a</sup></th></tr>\n</thead>\n<tbody>\n<tr><td>Very low risk of hypersensitivity (constitutes ~94% <sup>b</sup> of patients)</td><td>Absence of <em>*57:01</em> alleles (reported as &quot;negative&quot; on a genotyping test)</td><td>*X/*X <sup>c</sup></td><td>Low or reduced risk of abacavir hypersensitivity</td><td>Use abacavir per standard dosing guidelines</td><td>Strong</td></tr>\n<tr><td>High risk of hypersensitivity (~6% of patients)</td><td>Presence of at least one <em>*57:01</em> allele (reported as &quot;positive&quot; on a genotyping test)</td><td><em>*57:01</em>/*X <sup>c</sup> <em>*57:01/*57:01</em></td><td>Significantly increased risk of abacavir hypersensitivity</td><td>Abacavir is not recommended</td><td>Strong</td></tr>\n</tbody>\n</table>\n<p><sup>a</sup> Rating scheme described in the <a href=\"https://api.pharmgkb.org/v1/download/file/attachment/CPIC_HLAB-Abacavir_Supplemental_Material.pdf\">2012 Supplement</a></p>\n<p><sup>b</sup> See the <a href=\"https://api.pharmgkb.org/v1/download/file/attachment/CPIC_HLAB-Abacavir_Supplemental_Material.pdf\">2012 Supplement</a> for estimates of genotype frequencies among different ethnic/geographic groups</p>\n<p><sup>c</sup> *X = any <em>HLA-B</em> genotype other than <em>*57:01</em>.</p>\n<p><em>HLA-B</em> = human leukocyte antigen B</p>\n<p><strong>Listen to an interview with the lead author:</strong> <a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=http%3A%2F%2Fwww.theaidsreader.com%2Fdisplay%2Farticle%2F1145619%2F2064707\" target=\"_blank\">podcast</a></p>\n",
      "internalLinks" : [ "^attachment/CPIC_HLAB-Abacavir_Supplemental_Material.pdf" ],
      "markdown" : "## May 2014\r\n\r\n_Accepted article preview online 21 February 2014; Advance online publication 12 March 2014_\r\n\r\nThe [2014 update of CPIC guidelines](http://www.nature.com/clpt/journal/v95/n5/full/clpt201438a.html) regarding abacavir has been published in _Clinical Pharmacology and Therapeutics_. Literature published between April 2011-November 2013 was reviewed and there is __no new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current__. \r\n- These guidelines are applicable to:\r\n  - HIV Patients\r\n- Download and read:\r\n  - [Clinical Pharmacogenetics Implementation Consortium Guidelines for _HLA-B_ Genotype and Abacavir Dosing: 2014 Update ](https://github.com/PharmGKB/cpic-guidelines/raw/master/abacavir/2014/24561393.pdf).\r\n  - [2014 supplement](https://github.com/PharmGKB/cpic-guidelines/raw/master/abacavir/2014/24561393-supplement.pdf).\r\n\r\n## April 2012\r\n\r\n_Advance online publication February 2012_\r\n- Download and read:\r\n  - [Clinical Pharmacogenetics Implementation Consortium Guidelines for _HLA-B_ Genotype and Abacavir Dosing](https://github.com/PharmGKB/cpic-guidelines/raw/master/abacavir/2012/22378157.pdf) \r\n  - [2012 supplement](https://github.com/PharmGKB/cpic-guidelines/raw/master/abacavir/2012/22378157-supplement.pdf). \r\n\r\nExcerpt from the abacavir dosing guidelines:\r\n\r\n> We agree with others* that _HLA-B*57:01_ screening should be performed in all abacavir-naive individuals before initiation of abacavir-containing therapy (see Table 1 below); this is consistent with the recommendations of the FDA, the US Department of Health and Human Services, and the European Medicines Agency. In abacavir-naive individuals who are _HLA-B*57:01_-positive, abacavir is not recommended and should be considered only under exceptional circumstances when the potential benefit, based on resistance patterns and treatment history, outweighs the risk.\r\n\r\n\r\n*[PMID: 18826546, 19640227, 21174626, 21412232] [Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (PDF) ](http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf)\r\n\r\n\r\n## Table 1: Recommended therapeutic use of abacavir based on _HLA-B_ genotype\r\n\r\n_Adapted from Tables 1 and 2 of the 2012 guideline manuscript._\r\n\r\n| Likely phenotype | Genotypes | Examples of diplotypes | Implications for phenotypic measures   | Recommendations for abacavir therapy | Classification of recommendation for abacavir therapy ^a^ |\r\n| --- | --- | --- | --- | --- | --- |\r\n|Very low risk of hypersensitivity (constitutes ~94% ^b^ of patients) | Absence of _*57:01_ alleles (reported as \"negative\" on a genotyping test)| *X/*X ^c^|  Low or reduced risk of abacavir hypersensitivity  |  Use abacavir per standard dosing guidelines |  Strong |\r\n|High risk of hypersensitivity (~6% of patients) | Presence of at least one _*57:01_ allele (reported as \"positive\" on a genotyping test) | _*57:01_/*X ^c^ _*57:01/*57:01_ | Significantly increased risk of abacavir hypersensitivity| Abacavir is not recommended |  Strong |\r\n\r\n^a^ Rating scheme described in the [2012 Supplement](^CPIC_HLAB-Abacavir_Supplemental_Material.pdf)\r\n\r\n^b^ See the [2012 Supplement](^CPIC_HLAB-Abacavir_Supplemental_Material.pdf) for estimates of genotype frequencies among different ethnic/geographic groups\r\n\r\n^c^ *X = any _HLA-B_ genotype other than _*57:01_.\r\n\r\n_HLA-B_ = human leukocyte antigen B\r\n\r\n__Listen to an interview with the lead author:__ [podcast](http://www.theaidsreader.com/display/article/1145619/2064707)",
      "pmids" : [ "18826546", "19640227", "21174626", "21412232" ],
      "relatedObjects" : [ ],
      "version" : 9
    },
    "version" : 28,
    "xrefs" : [ {"@id":"https://api.pharmgkb.org/data/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-abacavir-and-hla-b/","@context":"https://www.pharmgkb.org/jsonld/crossReference.jsonld","id":1447983436,"resource":"Web Resource","sameAs":"https%3A%2F%2Fcpicpgx.org%2Fguidelines%2Fguideline-for-abacavir-and-hla-b%2F","xrefId":"https://cpicpgx.org/guidelines/guideline-for-abacavir-and-hla-b/"} ]
  },
  "annotationGroups" : [ {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128752",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128752",
    "name" : "Absent",
    "annotations" : [ {
      "id" : 1445560529,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986546,
        "externalLinks" : [ ],
        "html" : "<p>Low or reduced risk of abacavir hypersensitivity</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Low or reduced risk of abacavir hypersensitivity",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1445560765,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986547,
        "externalLinks" : [ ],
        "html" : "<p>Very low risk of hypersensitivity (~94% of patients) in the absence of *57:01 alleles (reported as &quot;negative&quot; on a genotyping test)</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Very low risk of hypersensitivity (~94% of patients) in the absence of *57:01 alleles (reported as \"negative\" on a genotyping test)",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1445560530,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986545,
        "externalLinks" : [ ],
        "html" : "<p>Use abacavir per standard dosing guidelines</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Use abacavir per standard dosing guidelines",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928",
        "version" : 0
      },
      "version" : 6
    } ],
    "genePhenotypes" : [ "HLA-B:Absence/Absence" ],
    "guideline" : {
      "objCls" : "Guideline",
      "@id" : "https://api.pharmgkb.org/data/guideline/PA166104997",
      "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
      "id" : "PA166104997",
      "name" : "CPIC Guideline for abacavir and HLA-B",
      "version" : 28
    },
    "rxChangeStatus" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/rxChange/rxChange:1448602495",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602495,
      "resource" : "Prescribing Change",
      "term" : "No",
      "termId" : "rxChange:1448602495",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "resource" : "Guideline Strength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930",
      "version" : 0
    },
    "version" : 6
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128753",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128753",
    "name" : "Present",
    "annotations" : [ {
      "id" : 1445561001,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986470,
        "externalLinks" : [ ],
        "html" : "<p>Significantly increased risk of abacavir hypersensitivity</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Significantly increased risk of abacavir hypersensitivity",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1445561000,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986548,
        "externalLinks" : [ ],
        "html" : "<p>High risk of hypersensitivity (~6% of patients) due to the presence of at least one *57:01 allele (reported as &quot;positive&quot; on a genotyping test)</p>\n",
        "internalLinks" : [ ],
        "markdown" : "High risk of hypersensitivity (~6% of patients) due to the presence of at least one *57:01 allele (reported as \"positive\" on a genotyping test)",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1445561002,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986471,
        "externalLinks" : [ ],
        "html" : "<p>Abacavir is not recommended</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Abacavir is not recommended",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928",
        "version" : 0
      },
      "version" : 6
    } ],
    "genePhenotypes" : [ "HLA-B:Absence/Presence", "HLA-B:Presence/Presence" ],
    "guideline" : {
      "objCls" : "Guideline",
      "@id" : "https://api.pharmgkb.org/data/guideline/PA166104997",
      "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
      "id" : "PA166104997",
      "name" : "CPIC Guideline for abacavir and HLA-B",
      "version" : 28
    },
    "rxChangeStatus" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/rxChange/rxChange:1448602495",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602495,
      "resource" : "Prescribing Change",
      "term" : "No",
      "termId" : "rxChange:1448602495",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "resource" : "Guideline Strength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930",
      "version" : 0
    },
    "version" : 6
  } ],
  "genePhenotypes" : {
    "HLA-B" : {
      "*57:01:01" : "Presence",
      "Other" : "Absence"
    }
  },
  "citations" : [ {
    "@id" : "https://api.pharmgkb.org/data/literature/24561393",
    "@context" : "https://api.pharmgkb.org/data/literature.jsonld",
    "id" : 15070904,
    "resourceId" : "24561393",
    "title" : "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update",
    "authors" : [ "Martin Michael A", "Hoffman James M", "Freimuth Robert R", "Klein Teri E", "Dong Betty J", "Pirmohamed Munir", "Hicks J Kevin", "Wilkinson Mark R", "Haas David W", "Kroetz Deanna L" ],
    "hasKeyword" : true,
    "journal" : "Clinical pharmacology and therapeutics",
    "meshDiseases" : [ ],
    "meshTerms" : [ ],
    "month" : 2,
    "nonHuman" : false,
    "pubDate" : "2014-02-01T00:00:00-08:00",
    "sameAs" : "https://www.ncbi.nlm.nih.gov/pubmed/24561393",
    "sentences" : [ {
      "location" : "title",
      "id" : 15070905,
      "text" : "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update",
      "sentenceIndex" : 0
    }, {
      "location" : "abstract",
      "id" : 15070906,
      "text" : "The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing was originally published in April 2012.",
      "sentenceIndex" : 1
    }, {
      "location" : "abstract",
      "id" : 15070907,
      "text" : "We reviewed recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current.",
      "sentenceIndex" : 2
    }, {
      "location" : "abstract",
      "id" : 15070908,
      "text" : "However, we have updated the supplemental material and included additional resources for applying CPIC guidelines into the electronic health record.",
      "sentenceIndex" : 3
    }, {
      "location" : "abstract",
      "id" : 15070909,
      "text" : "Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).Clinical Pharmacology & Therapeutics (2014); Accepted article preview online 21 February 2014.",
      "sentenceIndex" : 4
    }, {
      "location" : "abstract",
      "id" : 15070910,
      "text" : "doi:10.1038/clpt.2014.38.",
      "sentenceIndex" : 5
    } ],
    "summary" : "The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing was originally published in April 2012. We reviewed recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the supplemental material and included additional resources for applying CPIC guidelines into the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).Clinical Pharmacology & Therapeutics (2014); Accepted article preview online 21 February 2014. doi:10.1038/clpt.2014.38.",
    "type" : "article",
    "version" : 1,
    "year" : 2014
  }, {
    "@id" : "https://api.pharmgkb.org/data/literature/22378157",
    "@context" : "https://api.pharmgkb.org/data/literature.jsonld",
    "id" : 14962778,
    "resourceId" : "22378157",
    "title" : "Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing",
    "authors" : [ "Martin M A", "Klein T E", "Dong B J", "Pirmohamed M", "Haas D W", "Kroetz D L" ],
    "hasKeyword" : true,
    "journal" : "Clinical pharmacology and therapeutics",
    "meshDiseases" : [ ],
    "meshTerms" : [ ],
    "month" : 2,
    "nonHuman" : false,
    "pubDate" : "2012-02-01T00:00:00-08:00",
    "sameAs" : "https://www.ncbi.nlm.nih.gov/pubmed/22378157",
    "sentences" : [ {
      "location" : "title",
      "id" : 14962779,
      "text" : "Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing",
      "sentenceIndex" : 0
    } ],
    "type" : "article",
    "version" : 1,
    "year" : 2012
  } ]
}